当前位置:首页 > 报告详情

REDEFINE 1 试验中 CagriSema 平均剂量与体重减轻之间的关系.pdf

上传人: 表表 编号:1279996 2026-07-18 17页 372.54KB

1、Garvey WT et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Relationship between mean CagriSema dose and weight loss in the REDEFINE 1 trialW.Timothy Garvey1,Jaime Almandoz2,Mikkel Hovden Christensen3,Cynthia Karenina Osorto Contreras3,Anthony N.Fabricatore4,

2、Thomas Bo Jensen3,Michael G.Knight5,Kirsi H.Pietilinen6,7,Carel W.le Roux8,91Department of Nutrition Sciences,University of Alabama at Birmingham,Birmingham,AL,USA;2Department of Internal Medicine,University of Texas Southwestern Medical Center,Dallas,Texas,USA;3Novo Nordisk A/S,Sborg,Denmark;4Novo

3、Nordisk Inc.,Plainsboro,NJ,USA;5The George Washington University,Washington,DC,USA;6Obesity Research Unit,Research Program for Clinical and Molecular Metabolism,Faculty of Medicine,University of Helsinki,Helsinki,Finland;7Healthy Weight Hub,Abdominal Center,Helsinki University Hospital and Universit

4、y of Helsinki,Helsinki,Finland;8Diabetes Complications Research Centre,University College Dublin,Dublin,Ireland;9Diabetes Research Centre,Ulster University,Belfast,UKThis study was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT05567796).Medical writing support was provid

5、ed by James Parkinson,PhD,CMPP,of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022)Previously presented at the 43rd Annual Meeting of The Obesity Society held at ObesityWeek,47 November 2025,Atlanta,GA,USA

6、Scan QR code or visit the website below for:Science Hub linkshttps:/ WT et al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Presenter disclosure W.Timothy Garvey reports the following:Receiving consulting fees for advisory boards for Boehringer Ingelheim,Eli L

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **试验设计**:REDEFINE 1为III期随机双盲试验,评估CagriSema(每周皮下注射)联合生活方式干预对肥胖/超重患者的减重效果,允许剂量调整以模拟真实临床实践。 2. **核心减重数据**:CagriSema 2.4 mg/2.4 mg组平均减重22.7%,显著优于司美格鲁肽(16.1%)、卡格列肽(11.8%)和安慰剂(2.3%)。 3. **剂量与减重关系**:按维持期平均剂量分组(>0–0.5 mg、>0.5–1.0 mg、>1.0–1.7 mg、>1.7–2.4 mg),各组减重幅度分别为23.8%、23.7%、25.0%、22.6%,无明确线性关系。 4. **剂量调整原因**:57%患者完成试验时维持2.4 mg/2.4 mg剂量;剂量调整多因体重显著降低(如≥20%减重者占38.5%),而非仅因胃肠道不良反应(GI AE)。 5. **安全性**:高剂量组(>1.7–2.4 mg)基线BMI更高,GI AE发生率更低;低剂量组基线BMI较低,GI AE发生率更高。
**剂量与减重关系?** **减重效果因人而异?** **剂量调整如何影响疗效?**
客服
商务合作
小程序
服务号
折叠